SG11202011102TA - Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener - Google Patents

Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Info

Publication number
SG11202011102TA
SG11202011102TA SG11202011102TA SG11202011102TA SG11202011102TA SG 11202011102T A SG11202011102T A SG 11202011102TA SG 11202011102T A SG11202011102T A SG 11202011102TA SG 11202011102T A SG11202011102T A SG 11202011102TA SG 11202011102T A SG11202011102T A SG 11202011102TA
Authority
SG
Singapore
Prior art keywords
bioavailability
enhancing
exposure
voltage
methods
Prior art date
Application number
SG11202011102TA
Inventor
Gregory N Beatch
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of SG11202011102TA publication Critical patent/SG11202011102TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202011102TA 2018-05-11 2019-05-10 Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener SG11202011102TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670253P 2018-05-11 2018-05-11
PCT/US2019/031872 WO2019217924A1 (en) 2018-05-11 2019-05-10 Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Publications (1)

Publication Number Publication Date
SG11202011102TA true SG11202011102TA (en) 2020-12-30

Family

ID=66669101

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011102TA SG11202011102TA (en) 2018-05-11 2019-05-10 Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Country Status (31)

Country Link
US (2) US11135214B2 (en)
EP (2) EP4279133A3 (en)
JP (1) JP2021523130A (en)
KR (1) KR20210020892A (en)
CN (1) CN112384216A (en)
AU (1) AU2019265002A1 (en)
BR (1) BR112020022713A2 (en)
CA (1) CA3099292A1 (en)
CL (1) CL2020002932A1 (en)
CO (1) CO2020015476A2 (en)
CR (1) CR20200602A (en)
DK (1) DK3790548T3 (en)
EA (1) EA202092720A1 (en)
ES (1) ES2964409T3 (en)
FI (1) FI3790548T3 (en)
GE (1) GEP20237527B (en)
HR (1) HRP20231447T1 (en)
HU (1) HUE064326T2 (en)
LT (1) LT3790548T (en)
MA (1) MA52569B1 (en)
MD (1) MD3790548T2 (en)
MX (1) MX2020012008A (en)
PE (1) PE20211211A1 (en)
PH (1) PH12020551898A1 (en)
PL (1) PL3790548T3 (en)
PT (1) PT3790548T (en)
RS (1) RS64922B1 (en)
SG (1) SG11202011102TA (en)
SI (1) SI3790548T1 (en)
UA (1) UA127229C2 (en)
WO (1) WO2019217924A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3790548T3 (en) 2018-05-11 2023-11-17 Xenon Pharmaceuticals Inc Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
TW202128627A (en) 2019-10-10 2021-08-01 加拿大商再諾製藥公司 Solid state crystalline forms of a selective potassium channel modulator
KR20220113411A (en) * 2019-12-06 2022-08-12 제논 파마슈티칼스 인크. Use of KV7 potassium channel openers for the treatment of pain
CA3207191A1 (en) * 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia
WO2022173853A1 (en) * 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders
EP4074696A4 (en) * 2021-10-27 2024-01-31 Shanghai Zhimeng Biopharma Inc Compound as potassium channel regulator, and preparation and use thereof
CN113698345B (en) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 Compounds as potassium channel modulators, their preparation and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
CA2650853A1 (en) 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
MX2009002002A (en) * 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators.
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
FI3790548T3 (en) 2018-05-11 2023-11-17 Xenon Pharmaceuticals Inc Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Also Published As

Publication number Publication date
CR20200602A (en) 2021-03-02
AU2019265002A1 (en) 2020-12-03
EP3790548A1 (en) 2021-03-17
MX2020012008A (en) 2021-04-12
EP4279133A2 (en) 2023-11-22
CN112384216A (en) 2021-02-19
SI3790548T1 (en) 2024-02-29
EP4279133A3 (en) 2024-02-21
HUE064326T2 (en) 2024-03-28
MD3790548T2 (en) 2024-02-29
PT3790548T (en) 2023-11-23
MA52569A (en) 2021-03-17
PE20211211A1 (en) 2021-07-05
WO2019217924A1 (en) 2019-11-14
UA127229C2 (en) 2023-06-14
CO2020015476A2 (en) 2021-01-29
GEP20237527B (en) 2023-08-10
CL2020002932A1 (en) 2021-02-26
FI3790548T3 (en) 2023-11-17
CA3099292A1 (en) 2019-11-14
RS64922B1 (en) 2023-12-29
US11135214B2 (en) 2021-10-05
EP3790548B1 (en) 2023-08-23
US20190343823A1 (en) 2019-11-14
HRP20231447T1 (en) 2024-03-01
MA52569B1 (en) 2023-11-30
PL3790548T3 (en) 2024-03-11
BR112020022713A2 (en) 2021-02-02
EA202092720A1 (en) 2021-04-14
PH12020551898A1 (en) 2021-07-12
DK3790548T3 (en) 2023-11-13
JP2021523130A (en) 2021-09-02
ES2964409T3 (en) 2024-04-05
US20220062266A1 (en) 2022-03-03
LT3790548T (en) 2024-01-10
KR20210020892A (en) 2021-02-24

Similar Documents

Publication Publication Date Title
SG11202011102TA (en) Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
GB201604982D0 (en) Apparatus and method for opening a vehicle gate using a camera
IL283812B (en) Humanized anti-human-pd-1 antibody
EP3836435A4 (en) Channel prediction method and related device
IL282756A (en) Humanized anti-sirpα antibodies
IL272358B (en) Antigen-binding proteins that antagonize leptin receptor
IL277970A (en) Compounds and methods for reducing fxi expression
IL266106A (en) A monoclonal antibody and a method of use for the treatment of lupus
EP3541035A4 (en) Method and device for selecting channel
EP3517805B8 (en) Chain for screen device
GB201812641D0 (en) Riveting method
IL277296A (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
EP3900375A4 (en) Methods and apparatus for a window-metric rule
SG11202112850TA (en) Database language re-issue device
EP3878577A4 (en) Sliding gate apparatus
CA192396S (en) Case for door exit device
PT3702574T (en) Sunshade apparatus
IL284568A (en) Gate
CA187514S (en) Assistive device
PL3604724T3 (en) Gate
EP3569181C0 (en) Method for recycling metallic medical devices
PT3748876T (en) Interactive device for internet radio
GB201805894D0 (en) A method of abandoning a well
HK1246463A1 (en) Method and device for automatically selecting payment channel